NYSE:CVS

CVS Health Corp (CVS)

97.10
+0.02 (0.02%)
as of Jun 9, 2026, 3:24:57 pm Market Open.
411 watching
0
Investor Insights
star iconJun 9, 2026, 12:00 am

This summary was created by AI, based on 9 opinions in the last 12 months.

CVS Health Corp has recently demonstrated strong performance, beating earnings and revenue expectations, which has led to an increase in share value. Analysts highlight the company's strategic shift towards managed care, noting significant revenue growth in their health service division and pharmacy benefits. Despite potential concerns regarding the retail pharmacy's performance, the overall outlook appears promising as the management team effectively steers the company's turnaround. While some experts caution about the visible challenges and competition, they acknowledge that CVS's valuation is appealing compared to its peers in the healthcare sector, suggesting that the company may still have significant room for growth as it reinvents itself.

consensus icon
Consensus
Positive
valuation icon
Valuation
Undervalued
review icon
Similar
UNH
WATCH
Investor is down 25%.

Weak technical structure. 200-day MA falling, and stock price is below that. Longer-term weekly charts look just as tough. Earnings are tough in physical stores. Trump's (perhaps empty) threats to remove middle benefits management has impacted stock. Good yield at 5.81%, but how secure is it?

Keep a close eye on it, as technicals are telling you that things could get worse.

DON'T BUY

It's been problem after problem for them. Theft is forcing them to lose market share to Amazon. They're closing their worst-performing stores, opening health clinics and double-down on their non-drugstore businesses like Aetna and health insurance benefits manager. They have more than 900 medic clinics and 200 Oak Street health clinics. (Walgreens is reducing their clinics and Walmart got rid of all their clinics, because they can't find workers.) CVS bought Aetna 6 years ago, but managed care providers have been struggling for 1.5 years as people catch on post-Covid surgeries, which means paying out for those procedures. Meanwhile, Aetna dropped the ball on Medicare advantage plans for seniors; the plans were too cheap, which attracted many more customers, so people are using more healthcare services as the government is getting stingier with payments. Poor performance forced the CEO to be fired last October. Shares down -25% in December alone (healthcare stocks have fallen out of favour since the election and the Humana CEO murder). Then, Trump threatens to cut out the middlemen in health insurance. Just two days ago, the Justice Department slapped them with a lawsuit over controlled substances, which he thinks is damning. Their balance sheet is weak.

DON'T BUY

He sold it 3 months ago after holding it a long time. Shares keep falling. They fired their CEO. On paper, this stock looked good--reasonable valuation and good growth prospects, but they could never execute. There was always one piece in the vertical integration that failed them. That's why he left. The shares look cheap now, but can get cheaper. This is a value trap.

premiumPremium content

🔒 Premium Content Alert – This buzzing stock opinion is accessible only to Stockchase Premium

Discover an exclusive list and analysis of the stocks that are trending on social medias—accessible only to our Premium subscribers. With a keen focus on the stocks that are setting social media ablaze, this weekly feature offers an invaluable lens through which to evaluate market movers. Say goodbye to the endless scroll through social media timelines; we curate the buzz so you can invest your time as wisely as your money. Unlock Premium Now.

TOP PICK

CVS Health is building a world of health around every consumer. Our unmatched reach allows us to deliver high-quality, affordable health care when and how individuals choose. We’re on a mission to deliver superior and more connected experiences, lower the cost of care and improve the health and well-being of those we serve. Social media mentions are up 136% in the past 24h.

TOP PICK

Not only pharmacies, but offer health insurance, home care, pharmacy benefits management. CVS is the best-positioned healthcare company in the US. Trades at only 10x PE and pays a 5% dividend yield. He expects double-digit earnings growth in coming years despite the soft retail environment. Problems with Medicaid reimbursement should ease with the new administration and looser regulation.

(Analysts’ price target is $67.65)
DON'T BUY

It has taken one step forward and two steps backward for some time. The insurance business and pharmacy stores are holding it back. Only 75% of its stores are profitable. There are offers from Walmart and others to provide same day delivery services and this takes business away from CVS.

BUY

Recently bought. A laggard with a low valuation. A better choice than high-flying names.

SELL

Many headwinds, too big to overcome. Sell, take the loss.

PAST TOP PICK
(A Top Pick Sep 06/23, Down 10%)

He is expecting some relief on the regulatory side with less competition. It has a solid dividend yield and lots of cash flow. The stock looks cheap but the earnings are flat-lining.

DON'T BUY

200-day MA moving lower, stock price is below that. Basing since May. Retail side is the issue. Declining foot traffic, people are buying online. Integration problems with its various businesses. Earnings growth looks weak. 

He prefers growthier names, drug distribution, and traditional pharma like BMY.

WATCH

They report Wednesday. Listen for what the CEO has to say. He has a big job, because CVS has very jumbled assets. He wishes him the best.

PAST TOP PICK
(A Top Pick Nov 28/23, Down 13%)

Still owns it and still believes has great assets. It's down because of management turnover and bad capital allocations, but it's fixable and the business is not dead. He has faith in new management.

DON'T BUY

They cut forecasts and changed their CEO. This continues to get punished (glad he sold it last spring). An aging population is cutting deeply into their margins. Recently, they were talking about breaking up the company. Let's see if the new CEO can right the ship.

DON'T BUY

Pharmacy side not doing well, as people are switching to online. Pharmacy benefits are doing OK. Basing since May. Seems to be trying to get above water; just today got above the 200-day MA. See if it stays there.

Long term, managed care might be where they'll be OK. Valuation discount in the stock price, but it's a value trap. 9-10x forward earnings, but growth rate is under 2%. He doesn't like to buy on activist shareholders getting in, because you don't really know what's going to happen. He buys based on numbers, with earnings growth in high single digits.

PARTIAL SELL
A strategic review

It's been miserable and was exiting some of his position today. Maybe they will sell some of their businesses. Operating insurance and providing benefits has raised their costs and growth a lot. Regulations have also hurt. He doesn't see growth.

Showing 16 to 30 of 464 entries